Gustavo J. Pesquin
Chief Executive Officer chez KADMON HOLDINGS, INC.
Profil
Gustavo J.
Pesquin is currently the Chief Executive Officer at Asklepios BioPharmaceutical, Inc. since 2023 and at Kadmon Holdings, Inc. since 2021.
Previously, he held the position of Head-North America General Medicines at Sanofi US Services, Inc. and Chief Commercial Officer-Specialty & Executive VP at Amneal Intermediate, Inc. Mr. Pesquin completed his undergraduate degree at Universidad Nacional de Cuyo and holds an MBA from Kellogg School of Management.
Postes actifs de Gustavo J. Pesquin
| Sociétés | Poste | Début |
|---|---|---|
| KADMON HOLDINGS, INC. | Chief Executive Officer | 09/11/2021 |
Asklepios BioPharmaceutical, Inc.
 Asklepios BioPharmaceutical, Inc. BiotechnologyHealth Technology Asklepios BioPharmaceutical, Inc. operates as a gene therapy-based company. It engages in capsid development, scaled manufacturing, and a portfolio of therapeutic programs. The company was founded by Richard Jude Samulski, Xiao Xiao, and Sheila A. Mikhail in 2001 and is headquartered in Durham, NC. | Chief Executive Officer | 11/03/2023 |
Anciens postes connus de Gustavo J. Pesquin
| Sociétés | Poste | Fin |
|---|---|---|
Sanofi US Services, Inc.
 Sanofi US Services, Inc. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Sanofi US Services, Inc. engages in the research, production and distribution of pharmaceutical products. The private company is based in Bridgewater, NJ. | Corporate Officer/Principal | - |
Amneal Intermediate, Inc.
 Amneal Intermediate, Inc. Pharmaceuticals: MajorHealth Technology Amneal Intermediate, Inc. is a pharmaceutical company, which engages in the development, manufacture, market and distribution of generic pharmaceutical products. It operates through the Generic, Specialty and AvKARE Segments. The Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products and transdermals. The Specialty segment provides proprietary medicines to the U.S. market. The AvKARE segment focuses on pharmaceuticals, medical and surgical products, and services primarily to governmental agencies. The company was founded by Chintu Patel and Chirag Patel in 2002 and is headquartered in Bridgewater, NJ. | Corporate Officer/Principal | - |
Formation de Gustavo J. Pesquin
| Universidad Nacional de Cuyo | Undergraduate Degree |
| Kellogg School of Management | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Asklepios BioPharmaceutical, Inc.
Asklepios BioPharmaceutical, Inc. BiotechnologyHealth Technology Asklepios BioPharmaceutical, Inc. operates as a gene therapy-based company. It engages in capsid development, scaled manufacturing, and a portfolio of therapeutic programs. The company was founded by Richard Jude Samulski, Xiao Xiao, and Sheila A. Mikhail in 2001 and is headquartered in Durham, NC. | Health Technology |
Kadmon Holdings, Inc.
 Kadmon Holdings, Inc. BiotechnologyHealth Technology Kadmon Holdings, Inc. is a biopharmaceutical company, which engages in discovering, developing, and commercializing small molecules and biologics to address unmet medical need. The company's clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies. The firms late-stage product candidate KD025, which is an orally administered selective inhibitor of Rho-associated coiled-coil kinase engages in development for the treatment of inflammatory and fibrotic diseases. The firm's a pivotal clinical trial of KD025 is underway in chronic graft-versus-host disease (cGVHD), as well as a Phase 2 clinical trial in systemic sclerosis. It is also developing next-generation immuno-oncology therapies, specifically IL-15 containing fusion proteins, for the treatment of cancer. The company's lead I-O product candidate, KD033, is an anti-PD-L1/IL-15 fusion protein. Kadmon was founded by Steven N. Gordon in September 2010 and is headquartered in New York, NY. | Health Technology |
Sanofi US Services, Inc.
Sanofi US Services, Inc. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Sanofi US Services, Inc. engages in the research, production and distribution of pharmaceutical products. The private company is based in Bridgewater, NJ. | Health Technology |
Amneal Intermediate, Inc.
Amneal Intermediate, Inc. Pharmaceuticals: MajorHealth Technology Amneal Intermediate, Inc. is a pharmaceutical company, which engages in the development, manufacture, market and distribution of generic pharmaceutical products. It operates through the Generic, Specialty and AvKARE Segments. The Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products and transdermals. The Specialty segment provides proprietary medicines to the U.S. market. The AvKARE segment focuses on pharmaceuticals, medical and surgical products, and services primarily to governmental agencies. The company was founded by Chintu Patel and Chirag Patel in 2002 and is headquartered in Bridgewater, NJ. | Health Technology |
